Sunmax Biotechnology Co

Sunmax Biotechnology Co Gross Margin

The Gross Margin of Sunmax Biotechnology Co (4728.TWO) as of Nov 4, 2026 is 78.41 %. In the previous year, Gross Margin was 81.33 % — a change of -3.60% (lower).

Gross Margin

78.41 %

YoY

-3.60%

Last updated:

Gross Margin of Sunmax Biotechnology Co is 2025 78.41 % . Gross Margin of Sunmax Biotechnology Co was 2024 81.33 % . It decreases by -3.60% lower compared to the previous year.

For Sunmax Biotechnology Co, the gross margin of 78.4% is down versus 86.4% a few years ago.

The Sunmax Biotechnology Co Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
79.03 TWD
Jan 1, 2019
86.54 TWD
Jan 1, 2020
81.93 TWD
Jan 1, 2021
86.37 TWD
Jan 1, 2022
85.20 TWD
Jan 1, 2023
83.18 TWD
Jan 1, 2024
81.33 TWD
Jan 1, 2025
78.41 TWD
The Sunmax Biotechnology Co Gross Margin history
YEARGross MarginYoY
78.41 %-3.60%
81.33 %-2.22%
83.18 %-2.37%
85.20 %-1.35%
86.37 %+5.41%
81.93 %-5.33%
86.54 %+9.50%
79.03 %+9.22%
72.36 %+13.52%
63.74 %+6.47%
59.87 %-1.85%
61.00 %+9,252.87%
0.65 %-4.13%
0.68 %-12.55%
0.78 %+7.97%
0.72 %+13.18%
0.64 %+22.26%
0.52 %+147.53%
0.21 %-424.20%
-0.06 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sunmax Biotechnology Co Stock analysis

What does Sunmax Biotechnology Co do? SunMax Biotechnology Co., Ltd. generates revenue through the development, manufacturing, and commercialization of medical devices, biomedical materials, and bio surgical products. Its major products include collagen, collagen implants, microfiber collagen hemostat, collagen absorbable hemostat pads, healthcare products, and medical collagen application equipment. These products are sold to customers in the medical and beauty care industries across Taiwan, Mainland China, and other regions. The company's distribution focuses on these key markets, leveraging its product portfolio for healthcare and aesthetic applications. The firm's product line targets both medical and beauty care sectors, with collagen-based solutions serving as core offerings. Medical collagen application equipment supports clinical procedures, while collagen implants and hemostat products address surgical and wound care needs. The company's presence in Taiwan, Mainland China, and other regions enables it to serve diverse healthcare markets with standardized product offerings. SunMax Biotechnology's revenue streams are derived from the sale of collagen-based medical devices and equipment, with a focus on applications in surgery, wound care, and aesthetic treatments. By distributing its products through established channels in Taiwan, Mainland China, and other regions, the company capitalizes on demand for biocompatible materials in healthcare and beauty care industries. Sunmax Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sunmax Biotechnology Co stock

Gross Margin of Sunmax Biotechnology Co is 78.41 % in 2025.

Gross Margin of Sunmax Biotechnology Co changed from 81.33 % to 78.41 %, representing a -3.60% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Sunmax Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Sunmax Biotechnology Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Sunmax Biotechnology Co

All Key Metrics — Sunmax Biotechnology Co